Resuscitation Uncertain: Can Debiopharm Help Revive Pfizer's Failed Melanoma Drug?

After pharmacogenetic analysis in a Phase II melanoma study for tremelimumab failed to yield any clinically meaningful gene-response markers, Pfizer inked a codevelopment deal with Debiopharm handing over Phase III development of the drug with a protein marker linked to response. But commercialization rights still belong to Pfizer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.